Article citationsMore>>

Jensterle, M., Kravos, N.A., Pfeifer, M., Kocjan, T. and Janez, A. (2015) A 12-Week Treatment with the Long-Acting Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Leads to Significant Weight Loss in a Subset of Obese Women with Newly Diagnosed Polycystic Ovary Syndrome. Hormones, 14, 81-90.

has been cited by the following article:

• TITLE: Liraglutide (Saxenda®) as a Treatment for Obesity

  AUTHORS: Erin St. Onge, Shannon A. Miller, Carol Motycka

  KEYWORDS: Diabetes, Liraglutide, Obesity, Treatment

  JOURNAL NAME: Food and Nutrition Sciences, Vol.7 No.4, April 20, 2016

  ABSTRACT: Obesity is a significant concern in the United States, affecting approximately 35% of the population. Comorbidities, such as diabetes, hypertension, and hyperlipidemia, significantly increase one’s risk of heart attack, stroke, and even death. Liraglutide, a medication originally used to treat diabetes, has been approved for the treatment of obesity. Clinical trials have shown significant improvements in body weight and body mass index (BMI) at a dose of up to 3.0 mg daily. The most common adverse effects are gastrointestinal in nature, however, these often subside with time. Safety concerns with regards to thyroid tumors and pancreatitis should be carefully considered prior to use of this agent. Liraglutide should be considered an additional tool in the treatment of obesity, especially in patients with concomitant diabetes.